Flagship Pioneering | Activity

Team Change

Flagship Pioneering appointed Fidah Alsagoff as Executive Partner and Head of Global Initiatives, and Maggie Sahlman as Executive Partner and Head of Fundraising and Investor Relations, both newly created roles to expand global innovation ecosystem and fundraising.

Flagship Pioneering strengthens leadership team with two executive appointments

Flagship Pioneering

flagshippioneering.comAUG 3, 2026

AUG 3, 2026

Investment

Launched Serif Biomedicines with $50M in founding capital to develop modified DNA genetic medicines.

Serif Biomedicines

Serif Biomedicines Flagship Pioneering

biopharmadive.comAPR 21, 2026 flagshippioneering.com

APR 21, 2026

News

Announced an AWS collaboration to give Flagship companies cloud credits, technical support, and AI capabilities for life sciences innovation.

AWS collaboration

Flagship Pioneering

flagshippioneering.comAPR 1, 2026

APR 1, 2026

Team Change

Flagship Pioneering appointed Dr. Eric Topol as Academic Advisor to work primarily with its Preemptive Health and Medicine Initiative, guiding efforts to advance preemptive health interventions for chronic conditions including cancer, cardiometabolic, immune system disorders, and neurodegenerative diseases.

Flagship Pioneering appoints Eric Topol as Academic Advisor

Flagship Pioneering

flagshippioneering.comMAR 17, 2026

MAR 17, 2026

Exit

Portfolio company Generate:Biomedicines completed IPO on Nasdaq with $400M in proceeds.

Generate Biomedicines

Generate Biomedicines Flagship Pioneering

reuters.comFEB 27, 2026

FEB 27, 2026

Essay

Noubar Afeyan published his 2026 Annual Letter titled "Choosing Science," arguing for defending the scientific method against funding cuts and skepticism, highlighting 2025's biotech breakthroughs as "human-made miracles," and describing the convergence of human, machine, and nature's intelligence (polyintelligence).

Noubar Afeyan publishes 2026 Annual Letter "Choosing Science"

Flagship Pioneering

flagshippioneering.comJAN 12, 2026

JAN 12, 2026

Essay

Published Noubar Afeyan's 2026 annual letter arguing for renewed commitment to scientific research, biotechnology innovation, and AI-enabled discovery.

Choosing Science

Flagship Pioneering

flagshippioneering.comJAN 12, 2026

JAN 12, 2026

Essay

Noubar Afeyan's annual letter on the scientific method, biotech breakthroughs, and the importance of science-based policy.

Choosing Science - 2026 Annual Letter

Flagship Pioneering

flagshippioneering.comJAN 12, 2026

JAN 12, 2026

Investment

Unveiled Expedition Medicines with $50M in founding capital for AI-powered drug discovery platform.

Expedition Medicines

Expedition Medicines Flagship Pioneering

flagshippioneering.comOCT 2025 flagshippioneering.com

OCT 2025

Investment

Unveiled Extuitive with an initial $20M seed commitment to build AI-native product innovation and creative marketing tools.

Extuitive

Extuitive Flagship Pioneering

flagshippioneering.comSEP 18, 2025

SEP 18, 2025

Flagship Pioneering Activity

Flagship Pioneering appointed Fidah Alsagoff as Executive Partner and Head of Global Initiatives, and Maggie Sahlman as Executive Partner and Head of Fundraising and Investor Relations, both newly created roles to expand global innovation ecosystem and fundraising.

Sail Biomedicines, a Flagship company, announced a strategic collaboration with Johnson & Johnson to develop In Vivo CAR-T therapies for immune-mediated diseases, with initial payments of $785M including a $465M equity investment, and an exclusive option to acquire for $2.58B.

Launched Serif Biomedicines with $50M in founding capital to develop modified DNA genetic medicines.

Announced an AWS collaboration to give Flagship companies cloud credits, technical support, and AI capabilities for life sciences innovation.

Portfolio company Generate:Biomedicines completed IPO on Nasdaq with $400M in proceeds.

Published Noubar Afeyan's 2026 annual letter arguing for renewed commitment to scientific research, biotechnology innovation, and AI-enabled discovery.

Noubar Afeyan's annual letter on the scientific method, biotech breakthroughs, and the importance of science-based policy.

Unveiled Expedition Medicines with $50M in founding capital for AI-powered drug discovery platform.

Unveiled Extuitive with an initial $20M seed commitment to build AI-native product innovation and creative marketing tools.